Drug Type γ-δT, Universal CAR-T |
Synonyms QH104A |
Target |
Action modulators |
Mechanism CD276 modulators(CD276 antigen modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ependymoma | Phase 1 | China | 28 Nov 2025 | |
| Glioblastoma | Phase 1 | China | 28 Nov 2025 | |
| High grade glioma | Phase 1 | China | 28 Nov 2025 | |
| Medulloblastoma | Phase 1 | China | 28 Nov 2025 | |
| Meningioma | Phase 1 | China | 28 Nov 2025 | |
| Central Nervous System Neoplasms | IND Approval | United States | 16 May 2025 | |
| Malignant glioma of brain | Preclinical | United States | 21 Mar 2025 |





